The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 07, 2021

Filed:

Dec. 23, 2016
Applicant:

Themis Bioscience Gmbh, Vienna, AT;

Inventors:

Erich Tauber, Muckendorf, AT;

Sabrina Schrauf, Mörbisch am See, AT;

Matthias Müllner, Pixendorf, AT;

Katrin Ramsauer, Vienna, AT;

Angelika Irmler, Vienna, AT;

Patrick Csar, Königstetten, AT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); A61P 31/14 (2006.01); A61K 39/165 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); B01D 15/38 (2006.01); B01J 20/282 (2006.01); C12N 7/02 (2006.01); B01D 15/36 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); A61K 39/165 (2013.01); A61P 31/14 (2018.01); B01D 15/3804 (2013.01); B01J 20/282 (2013.01); C12N 7/00 (2013.01); C12N 7/02 (2013.01); C12N 15/86 (2013.01); B01D 15/361 (2013.01); C12N 2760/00034 (2013.01); C12N 2760/00051 (2013.01); C12N 2760/18051 (2013.01); C12N 2760/18434 (2013.01); C12N 2760/18443 (2013.01); C12N 2770/24121 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2800/22 (2013.01); C12N 2840/105 (2013.01); Y02A 50/30 (2018.01);
Abstract

The present invention relates to the provision of immunogenic or vaccine compositions comprising at least one recombinant Zika virus antigen, wherein the at least one recombinant Zika virus antigen is encoded by at least one nucleic acid sequence encoding at least one E-protein of a Zika virus or a functional fragment thereof. Further provided are nucleic acid molecules and a recombinant chimeric virus encoding and/or comprising selected antigens from a Zika virus, which are suitable as vaccine compositions. Preferably, the sequences encoding at least one Zika virus antigens suitable for eliciting an immune response are operably linked to a non-flavivirus derived vector backbone. Further provided are methods for purifying the recombinant chimeric virus particles or the immunogenic composition. Finally, there is provided an immunogenic/vaccine composition for use in a method of preventing or treating a Zika virus disease.


Find Patent Forward Citations

Loading…